Table 1.
Baseline characteristics of patients in the trials included in the meta-analysis
| Study | Number | Mean age (range, years) |
Tumor size (cm) |
Tumor histology | Follow-up (months) |
|---|---|---|---|---|---|
| Hayashi et al15 | 22 | 73 (60–80) | ≤1.0 | NR | NR |
| Noguchi et al16 | 10 | 54 (33–70) | <2.0 | Invasive ductal/intraductal carcinoma: 7/3 | NR |
| Izzo et al17 | 26 | 57 (37–78) | 1.8 (0.7–3.0) | Infiltrating ductal/lobular/tubular: 17/6/3 | NR |
| Wiksell et al18 | 33 | NR (46–83) | 0.6–1.5 | Ductal/lobular/mucinous/tubular: 26/2/1/4 | 55±21 |
| Wilson et al19 | 40 | 68.8±10.9 | 0.2–2.6 | NR | 1–60 |
| Palussière et al20 | 21 | 79 (70–88) | <3.0 | Invasive ductal/lobular/mucinous carcinoma: 17/3/1 | 49.6 (17–77) |
| Burak et al21 | 10 | 53.7 (37–67) | 1.15 (0.8–1.5) | NR | NR |
| Ohtani et al22 | 41 | 59 (38–92) | <2.0 | Invasive ductal/noninvasive ductal carcinoma: 36/5 | NR |
| Medina-Franco et al23 | 25 | 55.3 (42–89) | 2.08 (0.9–3.8) | Infiltrating ductal/lobular/mixed carcinoma: 21/2/2 | 1–6 |
| Fornage et al24 | 21 | 56 (38–80) | <2.0 | Invasive ductal/lobular carcinoma: 19/2 | NR |
| Earashi et al25 | 17 | 55 (33–78) | 1.1 (0.5–2.4) | Invasive ductal/noninvasive ductal carcinoma: 21/3 | 1–6 |
| Oura et al26 | 52 | 55 (37–83) | 1.3 (0.5–2.0) | Ductal/invasive ductal/lobular/tubular: 7/42/2/1 | Every 2–3 |
| Yamamoto et al27 | 29 | 55.9 (38–78) | 1.28 (0.5–1.9) | NR | 17 (2–41) |
| Seki et al28 | 15 | 61 (36–82) | 1.7 (0.5–3.0) | Invasive ductal carcinoma: 15 | 18 |
| Tsuda et al29 | 28 | 36–82 | 2.21 (0.6–5.0) | Intraductal carcinoma: 28 | NR |
Abbreviation: NR, not reported.